A16 CME ACTIVITY

Case Study: A 71-Year-Old Male With Relapsed CLL and an 11q DeletionReview the case and determine the best course of treatment

A25 FEATURE

Is Ageism Affecting Patients with Prostate Cancer?A Look At Cancer Treatment Among Age Groups

A27 IN THE CLINIC

Managing Anticoagulation in Patients with Primary or Metastatic Brain Tumors

A32 VIEWPOINT

The Unsustainable Costs of Cancer Care:Guidelines to Alleviate Costs for Patients

MARCH/APRIL 2015 | VOL I, ISSUE 4 CancerTherapyAdvisor.com

FEATURING

1 Bone Cancer

3 Brain Cancer

5 Breast Cancer

17 Endocrine Cancer

20 Gastrointestinal Cancer

29 Genitourinary Cancer

37 Gynecologic Cancer

42 Head and Neck Cancer

44 Hematologic Cancer

73 Lung Cancer

77 Sarcoma

80 Skin Cancer

84 Associated Hematological Disorders

Cancer Therapy Regimens and Oncology

Drug Monographs from

Regimen included

Can

cerTh

erapy

Ad

visor M

AR

CH

/AP

RIL

2015 | V

OL

I, ISSUE

4

A29 EXPERT PERSPECTIVE

Hot Topics From the 2015 Gastrointestinal Cancers Symposium

CTA_Cover_March-April 2015_F.indd 1 2/24/15 2:56 PM

haymarketoncologyBuilding Knowledge Through Practical Information

CANCER THERAPY ADVISOR | ONCOLOGY NURSE ADVISOR | ONA NAVIGATION SUMMIT

Bringing Navigation to the ForefrontJune 26-28, 2015Hyatt Regency DenverDenver, ColoradoCentennial Ballroom

This activity is jointly provided by Global Education Group and Oncology Nurse Advisor.

This activity is supported by educational grants from Astellas, Bristol-Myers Squibb, Celgene Corporation, Genentech, and Novartis Oncology

Guidance. Support. Knowledge.SUMMIT navigation CONFERENCE

GUIDE

PRINT | WEB | MOBILE 2016 MEDIA KIT

A F O R U M F O R P H Y S I C I A N A S S I S T A N T S

CANCER SCREENINGSimulation tool teaches clinical breast examination technique

PATIENT COUNSELING Overview of NCCN guidelines for smoking cessation

RADIATION & YOUR PATIENTPalliative radiotherapy

COMMUNICATION CHALLENGESConfirmation bias

FROM CANCERCAREUnique challenges for patients with lung cancer

DIAGNOSTIC TESTS

Liquid biopsies: A new tool for serial monitoring in the clinical setting

www.OncologyNurseAdvisor.com May/June 2015

■ Earn 0.5 contact hours

FREE CONTINUING EDUCATION INSIDE!Treatment of CLL using the principles of shared decision-making, PAGE 18

Circulating tumor cells and circulating tumor DNA entering the blood through vessel epithelium

DISCOUNTS & PROMOTIONAL OPPORTUNITIES

HAYMARKET CORPORATE DISCOUNTIndividual pharmaceutical companies and their subsidiaries may qualify for this additional discount based on their total gross spending in either 2015 or 2016. The amount of the discount when combining total gross spending for Cancer Therapy Advisor, Oncology Nurse Advisor, The Clinical Advisor, all MPR titles, McKnight’s Long-Term Care News, Assisted Living, Renal & Urology News, Psychiatry Advisor, Endocrinology Advisor, Neurology Advisor and Clinical Pain Advisor using 2015 rates is calculated after combo, continuity and special discounts are applied.

% Discount Total Gross $ off Gross

$ 250,000 – $ 750,000 2%

$ 750,001 – $1,500,000 3%

$1,500,001 – $2,500,000 5%

$2,500,001 – $3,500,000 7%

$3,500,001 + 10%

ANNUAL-CONTRACT OPTION5% discount on 2016 ad rates for all print space contracted and paid for by January 31, 2016. Contracts must stipulate the product(s), ad-unit size, colors, frequency, and specific dates of insertion in all editions.

COMBO DISCOUNTAdvertise in both Cancer Therapy Advisor and Oncology Nurse Advisor print editions and receive a 10% discount (ads must be for the same product; discount applies to ads of equal or lesser size)

IMPORTANT NOTE: In some instances, these discounts are mutually exclusive. Contact your Account Manager for details.

Publisher: Chad Holloway; (201) 799-4878 chad.holloway@haymarketmedia.comNational Sales Manager: Scott Bugni; (917) 882-0658 scott.bugni@haymarketmedia.comAccount Manager: Henry Amato; (646) 638-6096 henry.amato@haymarketmedia.comProduction Manager: Krassi Varbanov; (646) 638-6018 krassi.varbanov@haymarketmedia.comCirculation Manager: Paul Silver; (646) 638-6063 paul.silver@haymarketmedia.comManaging Editor, Haymarket Oncology: Lauren Burke; (201) 799-4866 lauren.burke@haymarketmedia.comSenior Digital Content Editor, Haymarket Oncology: Rick Maffei; (201) 799-4864 rick.maffei@haymarketmedia.comEditor, CTA: Lourdes Briz; (201) 799-2501 lourdes.briz@haymarketmedia.comDigital Editor, CTA: Stephan Cho; (646) 638-6024 stephan.cho@haymarketmedia.comEditor, ONA: Joyce Pagán; (201) 799-4803 joyce.pagan@haymarketmedia.comOncology Writer, Haymarket Oncology: Jason Hoffman, PharmD, RPh; (201) 755-5861 jason.hoffman@haymarketmedia.comGroup Art Director, Haymarket Medical: Jennifer DvoretzAssociate Art Director: Livvie ZurliniEditorial Director: Kathleen TulleySr. Vice President, Digital Products & Medical Magazines: Jim BurkeSenior Vice President, Clinical Communications: John PalCEO, Haymarket Media Inc.: Lee Maniscalco

CONTENTS

3 CTA Print

4 CTA Print Specs

5 CTA Digital Web

7 CTA Digital Mobile

8 CTA e-mail

9 ONA Print

10 ONA Print Specs

11 ONA Digital Web

13 ONA Digital Mobile

14 ONA e-mail

15 Advisor Channels

16 Brand Connect +Plus

17 ONA Navigation Summit

18 Custom Solutions

GENERAL INFORMATION

• 4 color: $5,845 per issue• 2 color: $4,562 per issue

Double your exposure with LINE ADS across the bottom of the drug monograph pages

Line Ad Packages (10 ads per issue)★

CONTENT INCLUDES• Cancer treatment regimens• Concise MPR drug monographs organized by

tumor type• Featured drugs and pipeline information• CME-accredited activity• Expert reviews, interviews, commentary, research

and analysis

PRINT FREQUENCY Every other month

PRINT CIRCULATION

Oncologists 3,829

Hematologist/Oncologists 4,998

Hematologists 1,337

Pediatric Hematologist/Oncologists 2,100

Other Oncology Specialists 993*

PA/NPs 825

Oncology Nurses 3,547

PharmDs in Hospital Settings 1,368

TOTAL 18,997

*Includes AMA file Gynecologic Oncologists, Musculoskeletal Oncologists, and IMs with a sub-specialty in Oncology

BONUS DISTRIBUTIONAmerican Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH)

CLOSING DATES 2016

ISSUE AD CLOSING MATERIALS

January/February December 4 December 10

March/April February 4 February 11

May/June April 6 April 12

July/August June 1 June 10

September/October August 1 August 5

November/ December October 7 October 14

Position Charges

Cover 2 25%

Section Index 15%

Cover 4 50%

All Other Guaranteed Positions

10%

4-Color Charge $2,530

PRICING & BILLING

Black & White Rates

1 PAGE

1× $6,400

6× $6,240

12× $6,090

24× $5,930

36× $5,810

48× $5,740

60× $5,690

72× $5,610

96× $5,510

120× $5,470

150× $5,410

CME ACTIVITY

CancerTherapyAdvisor.com | JANUARY/FEBRUARY 2015 | CANCER THERAPY ADVISOR A17

Review the case and determine the best course of treatment of a 63-year-old woman with gastric adenocarcinoma.

Case Study: A 63-Year-Old Hispanic Female With Gastric Adenocarcinoma

© E

VAN

OTO

/ S

CIE

NC

E SO

UR

CE

CASE OVERVIEWL.T., a 63-year-old Hispanic female, presented following a syncopal episode while walking down the street. On physical examination, the patient had a blood pressure of 128/72 mm Hg, a pulse of 64 beats per minute, a respira-tory rate of 20 breaths per minute, and a temperature of 37.6°C. Her laborato-ry evaluations revealed a hemoglobin level of 4.2 g/dL, a white blood cell count of 10.8 × 109/L, a hematocrit of 18.6%, and gross melena. Upper gas-trointestinal endoscopy demonstrates a large friable mass along the greater curvature of the stomach. Endoscopic ultrasound showed no adenopathy. A computed tomography (CT) scan also showed no adenopathy and no liver or lung lesions.

The patient received a transfusion of packed red cells and is then scheduled

for staging laparoscopy. This pro-cedure can help avoid unnecessary laparotomies and plan neoadjuvant treatment. One study has shown the positive predictive value for staging laparoscopy to be 96%, and the nega-tive predictive value, 50%, with mor-bidity in 98 patients to be 2.2% and mortality, 0%.1

Results of the staging laparoscopy show that the patient has stage II (T2, N1, M0) gastric adenocarcinoma.

CLINICAL DECISION POINT:What would be your next treat-ment step for L.T.?

A total of 50.5 million Americans—16% of the United States (US) population—identified themselves as Hispanic or Latino during the 2010 Census.2 Among Hispanics, cancer is the leading cause of death. In the US in 2014, an estimated 22,220 new cases of stomach cancer will

An illustration of gastric adenocarcinoma highlighting a mass along the curvature of the stomach.

CTA_CME_Jan-Feb2015_F.indd 17

1/14/15 5:09 PM

A16 CME ACTIVITY

Trends and Topics in the Management of Advanced Prostate Cancer

A debate between experts on clinical opinions that can create challenges in the treatment of prostate cancer.

A24 FEATURE

The 1%: Unraveling The Causes and Optimal Treatment Options for Men with Breast Cancer

A28 VIEWPOINT

Results of Nivolumab CheckMate 057 Study May Change Treatment of NSCLC

A30 IN THE CLINIC

Enoxaparin Ef� cacious, Feasible for Prevention of CTE in Advanced Pancreatic Cancer

JULY/AUGUST 2015 | VOL I, ISSUE 6 CancerTherapyAdvisor.com

FEATURING

1 Bone Cancer

3 Brain Cancer

5 Breast Cancer

12 Endocrine Cancer

16 Gastrointestinal Cancer

27 Genitourinary Cancer

37 Gynecologic Cancer

40 Head and Neck Cancer

41 Hematologic Cancer

63 Lung Cancer

76 Sarcoma

77 Skin Cancer

81 Associated Hematological Disorders

Cancer Therapy Regimens and Oncology

Drug Monographs from

Regimen included

Can

cerTh

erapy

Ad

visor JU

LY/A

UG

UST

2015 |

VO

L I, ISSU

E 6

A26 EXPERT PERSPECTIVE

A Case Study from an Oncology Sexual Health Clinic: Sexual

Dysfunction Evaluation

PRINT

PRODUCTION SPECSPRODUCTION CONTACT: cta.prodmngr@haymarketmedia.com

PRINTER: RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764

PRODUCTION SPECIFICATIONSInserts:• Trim size of the publication is 7 3/4’’ × 10 1/2’’• Maximum finished insert size is 8” × 10 3/4”

SHIPPINGInserts are to be in cartons on skid. Ship with publication name, issue date, and insert quantity clearly marked. Each issue packed separately.Delivery Address:RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764 Attn: James Dopler for CTA

QUANTITY: 20,500

INSERT DUE DATE: 25th of the month prior to publication

ADVERTISING• Final trim size must be 7 3/4’’ × 10 1/2’’• Live area: 7.25” × 10”• Bleeds must extend ¹/₈’’ past trim lines all around.

Thus, bleeds on all four sides mean that the bleeds extend out to 8” × 10 3/4”

• Live area for line ads: 6.875” × .75”

MECHANICAL SPECIFICATIONS• Hold Live Matter: 1/4” from trim• Type of Binding: Perfect bound• Material Policy: Reproduction material will be held 12

months from date of last insertion and then destroyed.

DIGITAL FILES• Include standard trim, bleed, and center marks in all

separations and outside trim (no marks included in the “live” image area)

• Please supply PDFs as single pages. Export settings can be found here: http://www.rrdonnelley.com/ prepress/prepare/indesign/export-pdf.aspx

• A CD ROM and contact color proof of the file should also be sent to: Krassi Varbanov, Haymarket Media Inc., 114 West 26th Street, 4th Fl., New York, NY 10001

BELLY BANDS

Fold In SpecsTrim Size: 22.75” × 3.5” (flat)Stock: 70#-80#Color: 4/0 process over black, bleedBinding: glue tipped to a specific pagePricing Includes: standard postage to polybag with edition

Wrap Around SpecsTrim Size: 16.9375” × 4” (flat)Stock: 70#-80#, can not be UV coated Color: 4/0 process over black, bleedBinding: glue tipped around bookPricing Includes: standard postage to polybag with edition

Half PageTrim: 7.5” × 5.5”Stock: 100# text matte preferred (gloss also accepted)Color: 4/0 Binding: glue tipped to coverPricing Includes: standard postage to polybag with edition

Outside

Inside

HALF PAGE COVER TIPS

BELLYBAND/COVERTIP PRICING & PRINT MECHANICAL REQUIREMENTS

YOUR AD HERE

AMOUNT PRICEPER

UNIT

19,000 (full run) $20,000 $1.05

AMOUNT PRICEPER

UNIT

19,000 (full run) $20,000 $1.05

AMOUNT PRICEPER

UNIT

19,000 (full run) $15,000 $0.79

DIGITAL | WEB

CONTENT INCLUDES:• Cancer treatment regimens• Concise MPR drug monographs organized by

tumor type• Relevant clinical charts and medical calculators• Extensive clinical trial information• Expert reviews, perspectives, and commentary• Latest Oncology news and feature articles• Oncology-specific resources for patient-care

Leaderboard — 728 × 90

Half Page/Filmstrip — 300 × 600

Box Ad/Sidekick — 300 × 250

Box Ad/Sidekick (sidebar) — 300 × 250

Half Page/Filmstrip (sidebar) — 300 × 600

SUPPORTED AD UNITS:

Online Opportunities CPM Price (net/net)

Run of Site (ROS) Banner Ads1

• 25,000 impressions/month to any visitor to the site• 70% viewability

$106 $2,650/month

List-Match Targeted Banner Ads1

• Match your list to Cancer Therapy Advisor’s list of validated HCPs• Deliver your ads to only the HCPs you are targeting• Delivers 25,000 impressions/month (Impressions dependent on the results of the match)• Creation of a unique list by combining data points (e.g., multiple professions and/or

specialties, prescribing data, IDC-9 or CPT codes, etc) will be billed at the List Match Targeted Banner Ad price plus pass through costs to create the list

• 70% viewability

$282$7,050/mos

dependent on list match

Geo Targeted Campaigns Run of Site (ROS)2 0.5× premium on banner ad rates

HCP-Level Data — Professionally Targeted Campaigns3 2× premium on banner ad rates

Programmatic Buying

ROS: $115Profession-Targeted: $199Specialty-Targeted: $315

List-Matched Targeted: $425

Native Advertising Sponsorship (net/net)

Brand Connect• 14 day Native Advertising program• Pricing based on estimated impressions, posting fee, email drops, value of high impact placement on page(s)

and within content stream• All content is clearly marked as sponsored content throughout

$3,000

1. A minimum of two ad units required, campaigns with only one ad unit available are subject to a premium2. Available based on estimated inventory to the select geographies3. Provides HCP data (name, profession, etc.) for impressions and clicks on targeted ad campaigns

PRICING

DIGITAL | WEB

Home Page Opportunities Price (net/net)

Homepage Takeover1

• 100% SOV; own all ad inventory on the home page for 24 hours• Available for a maximum of two weeks each month

$957/day

$6,699/week

Prestitial• 100% SOV; sits “over” the site and all pages are routed through the ad• Appears once per unique visitor per 24 hours

$957/day

$6,699/week

Targeted Prestitial• Number of Impressions is dependent on the size of the target list

Ask Publisher

Interstitial• Number of impressions is dependent on estimated traffic to the section and if prestitial is also sold• Appears once per unique visitor per 24 hours

Ask Publisher

Contextual Opportunities Sponsorship (net/net)

Topic/Department/Section Takeover• 100% SOV for any Department of you choice• Advisor channels are not available for section takeovers

$5,500/month

First Report — Live Conference Coverage• 25% banner ad SOV on Home Page, articles, and emails• News posted daily on-site, app, and newsletters• Newsletters sent daily in addition to wrap-up after conference concludes• Video interviews with thought leaders at the conference• Estimated 25,000 impressions• Advertiser must supply at least 2 ad units

$8,500/conference

AUDIENCE PENETRATION

• More than 320,000 page views per month1

• Over 150,000 unique visitors per month1

• 32,500 plus newsletter opt-ins2

• 72% of users visit the site at least once a week3

• 44% of users return in less than one day3

1. Omniture, June 2015, CTA Monthly Report2. Silverpop, June 2015, CTA Monthly Report3. Omniture, September 2015, CTA Monthly Report

1. A minimum of two ad units required

Intersitial/Prestitial — 640 x 480

Intersitial/Prestitial — 300 x 600

Intersitial/Prestitial — 300 x 250

SUPPORTED AD UNITS: 

PRICING

DIGITAL | MOBILE

Smartphone — 300 × 50

Tablet — 728 × 90

MOBILE APP SUPPORTED AD UNITS: 

Leaderboard — 728 × 90

MOBILE WEB SUPPORTED AD UNITS: 

Half page — 300 × 600

Box Ad — 300 × 250

AUDIENCE PENETRATION

• More than 45,000 app downloads1

• More than 59,000 page views per month1

1. Omniture, June 2015, CTA Monthly report

Mobile App CPM

Run of Site (ROS) Banner1 $106

List Match Targeted1 $282

Geo Targeted 0.5× premium on banner ad rates

HCP Level Data 2× premium on banner ad rates

1. 70% viewability

Notes:• Animated gifs are permitted but only the first frame will display in many email clients. Please ensure the first frame has brand name and call to action.• For most third party ad servers sending over a noscript standard tag is acceptable.• DFA and Pointroll users must send over a 1×1 and click tracker.• Text ads can have a headline of 100 characters including spaces, plus body copy of 300 characters including spaces.

Mobile Web

Mobile App

DimensionsFriendly/

Rising Star Name

File Size Rich Media Third Party Ad Served

Site Served Static Image

HTML5 Accepted Animation Accepted

VendorsFlash

Accepted

728 × 90 Tablet

Leaderboard 30k Yes Yes Yes Yes Unlimited All No

300 × 600 Half Page 30k Yes Yes Yes Yes Unlimited All No

300 × 250 Box Ad 30k Yes Yes Yes Yes Unlimited All No

300 × 250 Smartphone

Mobile Leaderboard

30k Yes Yes Yes Yes Unlimited All No

320 × 50 Smartphone

Mobile Leaderboard

30k Yes Yes Yes Yes Unlimited All No

DimensionsFriendly/

Rising Star Name

File Size

Rich media

Third Party Ad Served

Site Served Static Image

HTML5 Accepted Animation Accepted

VendorsFlash

Accepted Expandable

728 × 90 Tablet

Full Page Flex, Pull, Slider, Filmstrip

30k Yes Yes Yes Yes Unlimited All No

300 × 50 Smartphone

Full Page Flex, Pull, Slider, Filmstrip

30k Yes Yes Yes Yes Unlimited All No320 × 480

(max)

320 × 50 Smartphone

Full Page Flex, Pull, Slider, Filmstrip

30k Yes Yes Yes Yes Unlimited All No

MOBILE SPECS

PRICING

-

EDITORIAL E-NEWSLETTERSMore than 35,500 opted-in healthcare professionals

Morning Rounds

Distributed every Tuesday through Friday to over 32,500 opted in HCPs. The Morning Rounds provides a not-to-be missed recap of the day’s top news and trending articles to keep our audience up to date.

Weekly Highlights

Distributed every Monday to over 35,500 opted in HCPs. The Weekly Highlights provides a complete overview of top rated oncology news and featured content from the previous week.

Spotlights

The CTA spotlights feature tumor-type-specific key research, news, and clinical commentary delivered to over 32,500 opted in HCPs covering the latest disease-state specific content.

Use your web ads on CTA e-Newsletters!

CTA supports animated GIFs in email, and we can include ISI as “text” below a 300 × 250 ad unit, in a uniquely formatted e-Mail that allows you to use your web ads on newsletters!

e-Newsletter Opportunities price (net/net)

Editorial e-Newsletters• 32,500+ opted-in validated HCPs

— Morning Rounds — Weekly Highlights — Spotlight

$3,000$3,000$4,000

Specialty Targeted e-Newsletters• Deliver your ad to only the specialty you

want to reach• Ads run on existing editorial e-Newsletter;

content is not changed

$2,500

List Match Targeted e-Newsletters: • Deliver your ad to only your target list• Ads run on existing editorial e-Newsletters;

content is not changed• Includes HCP level data

$5,000

DISCOUNTS* $500 off/drop for commitment to 3 or more drops* $1,000 off/drop for commitment to 6 or more drops

CUSTOM EMAIL MARKETING PROGRAMS• Email marketing provides timely and cost-

effective message delivery• Use CTA to target your “called on” or “no see” HCPs• Quickly measure ROI, including e-Mails delivered,

bounces, opens, click-throughs, etc• Include specific links to your branded or

unbranded site/portal

Custom e-Mail Blasts price (net/net)

xPress• Distribute pre-approved material to

target list of HCPs• Leverage the strength of CTA to cut

through the inbox clutter• Note: Additional fees apply if

newsletter needs legal review, tracking codes added, etc

• See Account Manager for required specs

$0.35/name + $1,500 setup fee;

sponsor provides content; list-matching charges apply

Minimum: $3,500 ($2,000 list fee plus

$1,500 set-up)

AlertHaymarket creates content; consult Account Manager

for details and pricing

Leaderboard — 728 × 90

Box Ad — 300 × 250

E-MAIL

SUPPORTED AD UNITS

PRINT

CONTENT INCLUDES• Side-effect management• Survivorship issues• Patient education and navigation• Safe handling and administration of medications• Impact of genomics/genetics on cancer treatment• Communication with patients, caregivers, and the

cancer care team

AUDIENCE PENETRATION• 72% read cover to cover or articles of interest and

look through the remaining pages1

• #4 readership ranking out of 14 publications reaching this audience1

• #2 ad page exposure ranking out of 14 publica-tions reaching this audience1

1. Kantar Media, Oncology Nursing 2015, Table 101 and Table 201

PRINT FREQUENCYEvery other month

PRINT CIRCULATION

Oncology Nurse 16,859

Nurse Practitioner 2,986

Physician Assistant 1,422

Director of Nursing 2,363

TOTAL 23,630

BONUS DISTRIBUTIONAmerican Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), Oncology Nursing Society (ONS), ONA Navigation Summit

CLOSING DATES 2016

ISSUE AD CLOSING MATERIALS

January/February January 20 January 25

March/April March 14 March 16

May/June May 10 May 13

July/August July 12 July 14

September/October September 13 September 15

November/December November 15 November 17

PRICING & BILLING:

Black & White Rates

1 PAGE

1× $4,030

6× $3,970

12× $3,910

24× $3,790

36× $3,640

48× $3,520

60× $3,470

72× $3,380

96× $3,320

120× $3,260

150× $3,220

4-Color Charge: $2,260

Inserts: Charged at the page for page black & white rate

Position Charges:

Cover 2 25%

TOC 15%

Cover 4 50%

All Other Guaranteed Positions

10%

18 ONCOLOGY NURSE ADVISOR • JANUARY/FEBRUARY 2014 • www.OncologyNurseAdvisor.com

FEATURE | Establishing survivorship programs

© T

HIN

KSTO

CK

DEB ROSS, BSN, RN, OCN

T he American Cancer Society (ACS) pub-lished some astonishing numbers in its report, Cancer Treatment and Survivorship

Facts and Figures 2012-2013. An estimated 13.7 million people in America are cancer survivors, and 59% of them are 65 years or older.1 This increasing population is in need of quality, evidence-based survivorship care. How to best serve this population with the resources available is challenging. When should survivorship care begin? This article explores the definition of cancer survivor and strategies for both inform-ing patients and engaging them in their care. DEFINING SURVIVORSHIPThe first Sunday in June is designated as National

Cancer Survivors Day. Mercy Cancer Centers, in Toledo, Ohio, has hosted a Cancer Survivor Celebration for the past 9 years. To promote the event, we post and hand out flyers to our patients. After handing a flyer to one patient, he replied, “I don’t know that I am a survivor yet.” When does a patient with cancer become a survivor?A major controversy in oncology is how to

define a cancer survivor. The National Cancer Survivors Day (NCSD) Foundation defines a cancer survivor as “anyone living with a history of cancer—from the moment of diagnosis through the remainder of life.”2 Understanding that sur-vivorship is not the end of treatment or being disease-free for a designated period of time is crucial to developing a survivorship program.

Continued on page 25

Establishing survivorship care in a community-based centerWhen should survivorship care begin? The definition of a cancer survivor and

strategies for educating and engaging survivors in their care are explored.Cancer survivor Anyone living with a history of cancer —from the moment of diagnosis through the remainder of life

of the disease in mice. Bisphosphonates are an existing class

of drugs that prevents the loss of bone mass and is already

used to treat diseases such as osteoporosis.

Metastatic breast cancer is the main cause of death from

breast cancer. The most common site for the disease to

spread is the bone, which occurs in approximately 85% of

patients with secondary breast cancer.

The findings suggest that identifying LOX in patients

with estrogen-receptor-negative breast cancer early could

allow doctors to block the enzyme’s activity. That would

prevent bone damage and the spread of tumor cells to the

bone and halt the progression of the disease.

Read more at http://bit.ly/1JeERtV

IN THE NEWS

TOP:

© T

HIN

KSTO

CK;

BO

TTO

M: ©

SC

IEPR

O /

SCIE

NC

E SO

URC

E

Scientists identify key to preventing

metastatic breast cancer

Scientists have identified a possible

key to preventing secondary cancers

in patients with breast cancer, after

discovering an enzyme that enhances

the spread of the disease. The enzyme

lysyl oxidase (LOX) released from the

primary tumor causes holes in bone

and prepares the bone for the future

arrival of cancer cells.

Further, the study found that treatment with a bisphos-

phonate prevented the changes in the bone and the spread

LCX found to cause

bone changes

Blood antibodies may predict survival in

HPV-positive oropharyngeal cancer

The presence of certain human papillomavirus (HPV)-16 antibodies in the blood was associated with improved

rates of survival among patients with HPV-related oropharyngeal carcinoma.

The incidence of HPV-positive oropharyngeal carcinoma has increased dramatically in recent years. Although

patients with HPV-positive disease have a better prognosis than those with HPV-negative disease, researchers are

still seeking a better understanding of what group of

patients is more likely to respond to treatment.

Researchers used blood samples from 209 patients

with previously untreated oropharyngeal carcinoma.

These samples included 96 who had confirmed HPV-

positive disease.

The research team screened the samples for HPV-

16 antibodies E1, E4-7, L1, L2, and the N-terminal and

C-terminal fragments of E2.

Patients who were positive for any of the E antibodies

tested had improved overall and progression-free survival

compared with those negative for the antibodies. The

5-year overall survival estimate for patients positive for E

antibodies was 87.4% compared with 42.2% for patients

negative for E antibodies. The 5-year progression-free survival estimate was 82.9% for antibody-positive patients

compared with 46.1% for antibody-negative patients.

Patients with HPV-positive disease who were also positive for the NE2, E1, or E6 antibodies had an 80% reduced

risk for death and a 70% reduced risk for disease progression.

No survival advantage was noted for the L antibodies tested in the study.

These data further suggest that if patient immunity can be modified to increase a patient’s E antibody response,

cancer outcomes might be affected. Clinical trials are now testing whether vaccines that can stimulate these

antibodies have clinical utility in HPV-related cancers.

10 ONCOLOGY NURSE ADVISOR • JULY/AUGUST 2015 • www.OncologyNurseAdvisor.com

ONA_IntheNews_0815.indd 10

7/24/15 1:39 PM

ON

COLO

GY N

URSE A

DVISO

R • JULY/A

UG

UST 2015

VOLU

ME 6, N

UM

BER 4

A F O R U M F O R P H Y S I C I A N A S S I S T A N T S

FEATUREDecline in cognitive function related to chemotherapy

RADIATION & YOUR PATIENT Survivorship care plans: The shift back to primary careCOMMUNICATION CHALLENGES Brave enough to let go

THE TOTAL PATIENT Palliative care and support for rural communities

FROM CANCERCAREProviding psychosocial care when

the patient is a child

BREAST CANCERInflammatory breast cancer: Identification and treatment options

www.OncologyNurseAdvisor.com

July/August 2015

■ Earn 1.00 contact hoursFREE CONTINUING EDUCATION INSIDE!Inflammatory breast cancer, PAGE 20

Inflammatory breast cancer symptoms include peau d’orange, redness, itching, warmth, and pain.

PRODUCTION SPECSPRODUCTION CONTACT: cta.prodmngr@haymarketmedia.com

PRINTER: RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764

PRODUCTION SPECIFICATIONSInserts:• Trim size of the publication is 7 3/4’’ × 10 1/2’’• Maximum finished insert size is 8” × 10 3/4”

SHIPPINGInserts are to be in cartons on skid. Ship with publication name, issue date, and insert quantity clearly marked. Each issue packed separately.Delivery Address:RR Donnelley, 1600 N. Main Street, Pontiac, IL 61764 Attn: James Dopler for ONA

QUANTITY: 20,500

INSERT DUE DATE: 25th of the month prior to publication

ADVERTISING• Final trim size must be 7 3/4’’ × 10 1/2’’• Live area: 7.25” × 10”• Bleeds must extend ¹/₈’’ past trim lines all around.

Thus, bleeds on all four sides mean that the bleeds extend out to 8” × 10 3/4”

• Live area for line ads: 6.875” × .75”

MECHANICAL SPECIFICATIONS• Hold Live Matter: 1/4” from trim• Type of Binding: Perfect bound• Material Policy: Reproduction material will be held 12

months from date of last insertion and then destroyed.

DIGITAL FILES• Include standard trim, bleed, and center marks in all

separations and outside trim (no marks included in the “live” image area)

• Please supply PDFs as single pages. Export settings can be found here: http://www.rrdonnelley.com/ prepress/prepare/indesign/export-pdf.aspx

• A CD ROM and contact color proof of the file should also be sent to: Krassi Varbanov, Haymarket Media Inc., 114 West 26th Street, 4th Fl., New York, NY 10001

BELLYBAND/COVERTIP PRICING & PRINT MECHANICAL REQUIREMENTS

YOUR AD HERE

BELLY BANDS

Fold In SpecsTrim Size: 22.75” × 3.5” (flat)Stock: 70#-80#Color: 4/0 process over black, bleedBinding: glue tipped to a specific pagePricing Includes: standard postage to polybag with edition

Wrap Around SpecsTrim Size: 16.9375” × 4” (flat)Stock: 70#-80#, can not be UV coated Color: 4/0 process over black, bleedBinding: glue tipped around bookPricing Includes: standard postage to polybag with edition

Half PageTrim: 7.5” × 5.5”Stock: 100# text matte preferred (gloss also accepted)Color: 4/0 Binding: glue tipped to coverPricing Includes: standard postage to polybag with edition

Outside

HALF PAGE COVER TIPS

AMOUNT PRICEPER

UNIT

19,000 (full run) $20,000 $1.05

AMOUNT PRICEPER

UNIT

19,000 (full run) $20,000 $1.05

AMOUNT PRICEPER

UNIT

19,000 (full run) $15,000 $0.79

Inside

DIGITAL | WEB

CONTENT INCLUDES

• Electronic access to information that enables quality oncology care

• Daily reports from the recent literature• Up-to-date drug information • Patient information and fact sheets• Point-of-care guides and tools• Interactivity with oncology colleagues

1. A minimum of two ad units required, campaigns with only one ad unit available are subject to a premium2. Available based on estimated inventory to the selected geographies3. Provides HDP data (name, profession, etc.) for impressions and clicks on targeted ad campaigns

Online Opportunities CPM Price (net/net)

Run of Site (ROS) Banner Ads1

• 25,000 impressions/month to any visitor to the site• 70% viewability

$75 $1,875/month

List-Match Targeted Banner Ads1

• Match your list to Oncology Nurse Advisor’s list of validated HCPs• Deliver your ads to only the HCPs you are targeting• Delivers 25,000 impressions/month (Impressions dependent on the results of the match)• Creation of a unique list by combining data points (e.g., multiple professions and/or

specialties, prescribing data, IDC-9 or CPT codes, etc) will be billed at the List Match Targeted Banner Ad price plus pass through costs to create the list

• 70% viewability

$207$5,175/mos

dependent on list match

Geo Targeted Campaigns Run of Site (ROS)2 0.5× premium on banner ad rates

HCP-Level Data — Professionally Targeted Campaigns3 2× premium on banner ad rates

Programmatic BuyingROS: $76

List-Match Targeted: $335

Native Advertising Sponsorship (net/net)

Brand Connect• 14 day Native Advertising program• Pricing based on estimated impressions, posting fee, email drops, value of high impact placement on page(s)

and within content stream• All content is clearly marked as sponsored content throughout

$2,500

PRICING

Leaderboard — 728 × 90

Half Page/Filmstrip — 300 × 600

Box Ad/Sidekick — 300 × 250

Box Ad/Sidekick (sidebar) — 300 × 250

Half Page/Filmstrip (sidebar) — 300 × 600

SUPPORTED AD UNITS:

DIGITAL | WEB

AUDIENCE PENETRATION• More than 179,000 page views per month1

• Over 98,000 unique visitors per month1

• 25,000 newsletter opt-ins2

• 59% of users visit the site at least once a week3

• 34%of users return in less than one day3

1. Omniture, June 2015, ONA Monthly Report2. Silverpop, June 2015, ONA Monthly Report3. Omniture, September 2015, ONA Monthly Report

Home Page Opportunities Price (net/net)

Homepage Takeover1

• 100% SOV; own all ad inventory on the home page for 24 hours• Available for a maximum of two weeks each month

$870/day

$6,090/week

Prestitial• 100% SOV; sits “over” the site and all pages are routed through the ad• Appears once per unique visitor per 24 hours

$870/day

$6,090/week

Targeted Prestitial• Number of Impressions is dependent on the size of the target list

Ask Publisher

Interstitial• Number of impressions is dependent on estimated traffic to the section and if prestitial is also sold• Appears once per unique visitor per 24 hours

Ask Publisher

Contextual Opportunities Sponsorship (net/net)

Topic/Department/Section Takeover• 100% SOV for any Department of you choice• Advisor channels are not available for section takeovers

$2,400/month

First Report — Live Conference Coverage• 25% banner ad SOV on Home Page, articles, and emails• News posted daily on-site, app, and newsletters• Newsletters sent daily in addition to wrap-up after conference concludes• Video interviews with thought leaders at the conference• Estimated 25,000 impressions• Advertiser must supply at least 2 ad units

$8,500/conference

1. A minimum of two ad units required

PRICING

Intersitial/Prestitial — 640 x 480

Intersitial/Prestitial — 300 x 600

Intersitial/Prestitial — 300 x 250

SUPPORTED AD UNITS: 

DIGITAL | MOBILE

Smartphone — 300 × 50

Tablet — 728 × 90

MOBILE APP SUPPORTED AD UNITS 

MOBILE WEB SUPPORTED AD UNITS Leaderboard — 728 × 90

Half page — 300 × 600

Box Ad — 300 × 250

AUDIENCE PENETRATION• More than 24,000 app downloads1

• More than 11,500 page views per month1

1. Omniture, June 2015 ONA Monthly report

Notes:• Animated gifs are permitted but only the first frame will display in many email clients. Please ensure the first frame has brand name and call to action.• For most third party ad servers sending over a noscript standard tag is acceptable.• DFA and Pointroll users must send over a 1×1 and click tracker.• Text ads can have a headline of 100 characters including spaces, plus body copy of 300 characters including spaces.

DimensionsFriendly/

Rising Star Name

File Size Rich Media Third Party Ad Served

Site Served Static Image

HTML5 Accepted Animation Accepted

VendorsFlash

Accepted

728 × 90 Leaderboard 30k Yes Yes Yes Yes Unlimited All No

300 × 600 Half Page 30k Yes Yes Yes Yes Unlimited All No

300 × 250 Box Ad 30k Yes Yes Yes Yes Unlimited All No

320x50 Smartphone

Mobile Leaderboard

30k Yes Yes Yes Yes Unlimited All No

DimensionsFriendly/

Rising Star Name

File Size

Rich media

Third Party Ad Served

Site Served Static Image

HTML5 Accepted Animation Accepted

VendorsFlash

Accepted Expandable

728 × 90 Tablet

Full Page Flex, Pull, Slider, Filmstrip

30k Yes Yes Yes Yes Unlimited All No

300 × 50 Smartphone

Full Page Flex, Pull, Slider, Filmstrip

30k Yes Yes Yes Yes Unlimited All No320 × 480

(max)

PRICING

Mobile App CPM

Run of Site (ROS) Banner1 $75

List Match Targeted1 $207

Geo Targeted 0.5× premium on banner ad rates

HCP Level Data 2× premium on banner ad rates

1. 70% viewability

Mobile Web

Mobile App

MOBILE SPECS

Smartphone — 320 × 50

E-MAIL

EDITORIAL E-NEWSLETTERSMore than 17,000 opted-in healthcare professionals

Editor’s Choice

The Editor’s Choice newsletter is distributed several times each week to over 18,000 opted-in health care providers. The Editor’s Choice keeps the Oncology Nurse Advisor audience informed of the top oncology news, and presents articles focusing on specific cancer types.

ONA Online

Focusing on exclusive online-only content, ONA Online newsletters feature answers to specific practice questions relevant to oncolgy nursing as well as timely medical conference coverage. The ONA Online newsletter is distributed to over 19,000 opted-in health providers.

Spotlight

The ONA spotlights feature key research, news, and clinical commentary to over 18,000 opted in oncology professionals on key topic-specific areas.

Use your web ads on ONA e-Newsletters!

ONA supports animated GIFs in email, and we can include ISI as “text” below a 300 × 250 ad unit, in a uniquely formatted e-Mail that allows you to use your web ads on newsletters!

e-Newsletter Opportunities price (net/net)

Editorial e-Newsletters• 25,000+ opted-in validated HCPs

— Editor’s Choice — ONA Online — Spotlight

$2,500$2,500$3,000

CUSTOM E-MAIL MARKETING PROGRAMS• E-Mail marketing provides timely and cost-

effective message delivery• Use ONA to target your “called on” or “no see”

HCPs• Quickly measure ROI, including e-Mails delivered,

bounces, opens, click-throughs, etc• Include specific links to your branded or

unbranded site/portal

Custom e-Mail Blasts price (net/net)

xPress• Distribute pre-approved material to

target list of HCPs• Leverage the strength of ONA to cut

through the inbox clutter• Note: Additional fees apply if newsletter

needs legal review, tracking codes added, etc

• See Account Manager for required specs

$0.35/name + $1,500 setup fee;

sponsor provides content; list-matching charges apply

Minimum: $3,500 ($2,000 list fee plus

$1,500 set-up)

AlertHaymarket creates content; consult Account Manager

for details and pricing

Leaderboard — 728 × 90

Box Ad — 300 × 250

DISCOUNTS* $500 off/drop for commitment to 3 or more drops* $1,000 off/drop for commitment to 6 or more drops

SUPPORTED AD UNITS

ADVISOR CHANNELS

PROGRAM OVERVIEW• Identify key content channels that offer an

opportunity to provide HCPs with more in-depth clinical information

• Haymarket provides all marketing to the Advisor Channel

• Engage a “channel specific” section editor to provide guidance on content

- Peer-to-peer, KOL multimedia product - Expert Perspectives - Clinical Viewpoints - Disease specific news, features, treatment

regimens and drug monographs• 25% SOV advertising sponsorship

Sponsorship provides a cost-effective, targeted, strategic message placement with multiple touchpoints to key targets

• 1 year of banner ads with minimum 25% SOV within onsite channel

• 1 year of banner ads with minimum 25% SOV within mobile channel

• Banner ad rotation in monthly Advisor e-Newsletter

• Investment: $80K (minimum 25% SOV)• Print ad in annual supplement to CTA• Digital ad in digital edition of annual

supplement to CTA

Metrics

• Total visits• Unique visits• Page views• Time spent on site• Video loads• Video plays• Lenght of video view

CONTENT DISSEMINATION

Multiple touch-points with key target audiences: Web, Email, Mobile, Print, Digital Edition

A24 FEATURE

Enhanced Ability to Predict Outcomes in Patients with RCCKey fi ndings from the 2015 American Urological Association annual meeting.

A21 VIEWPOINT

RCC May Reprogram to Minimize Immune Response Researchers focus on the impact of grade and its meaning for patients.

A22 VIEWPOINT

Robotic-Assisted Laparoscopic RadicalNephrectomyCollaboration leads to new approach for patient with metastatic disease.

SPECIAL EDITION:

Renal Cell Carcinoma

CTA_supp_Cover_RCC.indd 1 6/24/15 12:06 PM

Content

E-Mail

Banner Ads

Native Ads

Newsletter Ads

Reporting

PROGRAM OVERVIEW• Brand Connect connects Haymarket’s audiences with client materials • Asset Syndication (video or static) through Haymarket’s networks and channels• Multi-touchpoint strategy• $125,000 for 6 months

BRAND CONNECT +PLUS

BUY INCLUDES:• Hosting of client resource center containing

assets and links for six months• 25k ROS impressions per month• Six weeks of native ads (one per month)• Three custom e-blasts• Ads on one editorial newsletter per week• Triggered email message to users who visit

resource center

ONA NAVIGATION SUMMIT

EXHIBITOR $2,750

(Non-Profit $775)SILVER

$10,000GOLD

$15,000PLATINUM

$25,000

8” × 10” booth (non-profit tabletop) × × ×

Sponsor recognition on summit website — logo with link & company description 50 words - no logo 50 words 70 words 100 words

Sponsor listing in on-site program guide × × × ×

Sponsor recognition on signage and the summit × × × ×

Passport challenge × × × ×

Exhibit badges 2 4 4 6

Full conference registration badges 2 4 6

Conference bag insert × × ×

Sponsor level ribbon on staff badges × × ×

Conference guide ad 1/2 page Full page Full page

Premier booth location × × ×

Breakfast roundtable1 × ×

Co-sponsorship (breaks) × ×

General session lunch sponsor ×

Logo on conference bag ×

Door drop (1) ×

Verbal recognition during welcome ×

1. Breakfast Roundtable includes: Two 20-minute slots (7:00 am - 7:20 am & 7:30 am - 7:50 am) banquet table with tumor type/topic signage and sponsor logo, sponsor acts as moderator of table, roundtable sign up at Summit registration table, roundtable listing with sponsors logo in on-site conference guide

The conference was very well organized. Addressing needs of Navigation, both for a new and seasoned navigator. There was something useful, stimulating in each session. I would attend again.”

“

- Cindy Jones, BSN, RN, OCN, CTTS, Summa Heath Systems

(2015 Summit Attendee)

To learn about these and other sponsorship opportunities please contact our Event Sales Manager:Emily Andrewsemily.andrews@haymarketmedia.com(646) 638-6034

SPONSORSHIP OPPORTUNITIES

Charting Our Direction

haymarketoncology

April 7-9, 2016Gaylord Palms Resort & Convention CenterOrlando, Florida

ONANavigationSummit.com

2 0 1 6E X H I B I T O R P R O S P E C T U S

CUSTOM SOLUTIONS

Proven ability to deliver messages across a variety of media options

Concise Consult®Custom Pocket References

The Pocket GuideGeneric to Brand Reference and Pharmacy Facts

Informationprovided by

2012/2013 EDITION

Goodnews travels fast.Your trusted partner has launched a line of oral contraceptives.

Sandoz is bringing several generic options to pharmacies, and everyone should like the sound of that.

W

RESPIRATORY POckET REfEREncE

2014 EdITIOn

Compliments of

Integrated Prescribing Alert

xPress Direct Mail & Email Fact Pack®

Prsrt StdUS Postage

PAIDPermit #XXX

S. Hackensack, NJ

MPR PRescRibing AleRt®important information – Open immediately

QXR580602

ADHD Treatment

Option

PRI Healthcare Solutions, Division of Haymarket Media, Inc.25 Philips Parkway, Suite 104Montvale, NJ 07645

W13-164 Quillivant Env v8.indd 1 10/10/13 11:24 AM

PRESCRIBING ALERT®

Dear Healthcare Professional,

At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring you this PRESCRIBING ALERT about Quillivant XR™ (methylphenidate HCl) CII, a product of Pfizer Inc.Quillivant XR is a central nervous system stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD). The efficacy of Quillivant XR was established in a 2-week, placebo-controlled trial in children aged 6 to 12 years with a diagnosis of ADHD. Accumulated efficacy data from other methylphenidate products were also considered.Quillivant XR has been shown to improve classroom attention and behavior in children with ADHD. Quillivant XR demonstrated proven results starting at 45 minutes, 4 hours (primary endpoint), and continues to be effective to 12 hours post-dosing.

More information about the use of Quillivant XR is available at www.QuilliantXRPro.com.

SELECTED SafETy InformaTIonWarnInG: aBUSE anD DEPEnDEnCE

CnS stimulants, including Quillivant Xr, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

Please see Important Safety Information on the next page.Please see full Prescribing Information and Medication Guide,

including BOXED WARNING regarding Abuse and Dependence, enclosed in the envelope.

Sincerely,

Madonna Krawczyk, PharmD Director of Clinical Communications MPR Custom Programs

(Important Safety Information on next page)

RefeRence

1. Quillivant XR [prescribing information]. New York, NY: Pfizer Inc; 2013.

W13-164 Quillivant Letter v17.indd 1 10/10/13 11:23 AM

√ MPR PRescRibing AleRt

Quillivant XR™(methylphenidate HCl) CII

[√] First and only extended-release oral suspension for ADHD treatment ■ Quillivant XR™ (methylphenidate HCl) has once-daily administration—in the morning,

with or without food

SELECTED SAFETY INFORMATION

WARNING: ABUSE AND DEPENDENCECNS stimulants, including Quillivant XR, other methylphenidate-containing products, and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.

Company: Pfizer Inc.pharmacologic Class: Central nervous system stimulant.formulation: Extended-release oral suspension (concentration after reconstitution with water): 25 mg/5 mL (5 mg/mL).indication: For the treatment of attention deficit hyperactivity disorder (ADHD). The efficacy of Quillivant XR was established in a 2-week, placebo-controlled trial in children aged 6 to 12 years with a diagnosis of ADHD. Accumulated efficacy data from other methylphenidate products were also considered.dosing: •<6yrs: not established. •≥6yrs: Recommended starting dose: 20 mg (4 mL). •Once daily in the morning with or without food. •Dose may be titrated weekly in increments of 10 mg (2 mL) to 20 mg (4 mL); max 60 mg daily. •Dose should be individualized according to the needs and responses of the patient. •Shake vigorously for 10 seconds before each use. •Reevaluate periodically to assess the long-term usefulness in maintenance therapy. •Reduce dosage or discontinue therapy if patients exhibit paradoxical aggravation of symptoms or other side effects. •Discontinue drug if improvement is not observed after an appropriate dose adjustment over a one-month period.Contraindications: Known hypersensitivity to methylphenidate or product components. During or within 14 days of monamine oxidase inhibitors (MAOIs).

boxed Warning: high potential for abuse and dependence. Assess risk of abuse and monitor for signs of abuse and dependence while on therapy. Warnings & precautions: •Risk of sudden death in patients with known structural cardiac abnormalities, cardiomyopathy, serious arrhythmias, and coronary artery disease. Evaluate if chest pain, unexplained syncope, arrhythmias or other serious cardiac problems develop. •Monitor for hypertension and tachycardia. •May cause psychotic or manic symptoms in patients with no prior history. May exacerbate symptoms in patients with pre-existing psychiatric illness. Evaluate for bipolar disorder prior to use. •Peripheral vasculopathy including Raynaud’s phenomenon may develop, carefully observe for digital changes. •Monitor height and weight of children due to risk of long term suppression of growth. interactions: See Contraindications. Concomitant MAOIs can cause hypertensive crisis.special populations: Pregnancy (Cat. C). Nursing mothers: not recommended.Adverse reactions: Appetite decreased, insomnia, nausea, vomiting, dyspepsia, abdominal pain, weight decreased, anxiety, dizziness, irritability, affect lability, tachycardia, blood pressure increased.how supplied: Bottles of powder for reconstitution—300 mg/60 mL; 600 mg/120 mL; 750 mg/150 mL; 900 mg/180 mL.

(continued on next page)

Please see Important Safety Information and Indication on page 6.

Please see full Prescribing Information and Medication Guide, including BOXED WARNING regarding Abuse and Dependence, enclosed in the envelope.

1

Information summarized from Highlights section of Prescribing information. Please see Important Safety Information and Indication on page 6.

W13-164 Quillivant Alert v28.indd 1 10/10/13 2:31 PM

Print Digital

Print Digital

Dear Healthcare Professional,

At MPR we strive to bring you important drug information in a concise and timely fashion. In keeping with this goal, we are pleased to bring you this MPRxpress™ from GlaxoSmithKline and Theravance, makers of BREO® ELLIPTA™ (fluticasone furoate 100 mcg and vilanterol 25 mcg inhalation powder) for oral inhalation. Indications for BREO ELLIPTA • BREO ELLIPTA is a combination inhaled corticosteroid/long-acting beta2-adrenergic agonist (ICS/LABA) indicated for the long-term, once-daily, main-

tenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.• BREO ELLIPTA is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.• BREO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.

IMPORTANT SAFETY INFORMATION for BREO ELLIPTA WARNING: ASTHMA-RELATED DEATH• Long-acting beta2-adrenergic agonists (LABAs), such as vilanterol, one of the active ingredients in BREO ELLIPTA, increase the risk of

asthma-related death. A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABAs, including vilanterol.

• The safety and efficacy of BREO ELLIPTA in patients with asthma have not been established. BREO ELLIPTA is not indicated for the treatment of asthma.

Please see additional important prescribing information below.

BREO ELLIPTA is the only once-daily ICS/LABA (inhaled corticosteroid/long-acting beta2-agonist) for the maintenance treatment of COPD (chronic obstructive pulmonary disease). Once-daily BREO ELLIPTA provided sustained duration of action for a full 24 hours (as measured by FEV1.) Enclosed you will find the BREO ELLIPTA full prescribing information, as well as a product information sheet that highlights key points about BREO ELLIPTA and the Important Safety Information. If you would like to receive samples, please fill out and return the business reply card that is also included.

IMPORTANT SAFETY INFORMATION for BREO ELLIPTA CONTRAINDICATIONS• BREO ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to either

fluticasone furoate, vilanterol, or any of the excipients.

WARNINGS AND PRECAUTIONS• BREO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD.• BREO ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute

symptoms should be treated with an inhaled, short-acting beta2-agonist.• BREO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications

containing LABAs, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using BREO ELLIPTA should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.

• Oropharyngeal candidiasis has occurred in patients treated with BREO ELLIPTA. Advise patients to rinse the mouth without swallowing following inhalation to help reduce the risk of oropharyngeal candidiasis.

• An increase in the incidence of pneumonia has been observed in subjects with COPD receiving BREO ELLIPTA. There was also an increased incidence of pneumonias resulting in hospitalization. In some incidences these pneumonia events were fatal.

– In replicate 12-month studies of 3255 subjects with COPD who had experienced a COPD exacerbation in the previous year, there was a higher incidence of pneumonia reported in subjects receiving BREO ELLIPTA 100/25 mcg (6% [51 of 806 subjects]), fluticasone furoate (FF)/vilanterol (VI) 50/25 mcg (6% [48 of 820 subjects]), and FF/VI 200/25 mcg (7% [55 of 811 subjects]) than in subjects receiving VI 25 mcg (3% [27 of 818 subjects]). There was no fatal pneumonia in subjects receiving VI or FF/VI 50/25 mcg. There was fatal pneumonia in 1 subject receiving BREO ELLIPTA at the approved strength (100/25 mcg) and in 7 subjects receiving FF/VI 200/25 mcg (<1% for each treatment group).

• Physicians should remain vigilant for the possible development of pneumonia in patients with COPD, as the clinical features of such infections overlap with the symptoms of COPD exacerbations.

• Patients who use corticosteroids are at risk for potential worsening of existing tuberculosis; fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex. A more serious or even fatal course of chickenpox or measles may occur in susceptible patients. Use caution in patients with the above because of the potential for worsening of these infections.

Please see additional Important Safety Information for BREO ELLIPTA on back. Please see accompanying full Prescribing Information, including Boxed Warning and Medication Guide, for BREO ELLIPTA.

PRI Healthcare Solutions | Haymarket Oncology140 East Ridgewood Ave., Suite 176N, Paramus, NJ 07652

Learn more about an option in short-acting G-CSF therapyIMPORTANT INFORMATION – Open ImmediatelyONC-40794 June 2015

#897

If you would prefer not to receive further messages from MPR, please click here and confirm your request.

Monthly Prescribing Reference

Haymarket Media Inc.

114 W. 26th Street, 4th Floor

New York, NY 10001

IMPORTANT SAFETY INFORMATION

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close observation and communication with the prescriber. FETZIMA is not approved for use in pediatric patients.

CONTRAINDICATIONS • FETZIMA is contraindicated in patients with a hypersensitivity to levomilnacipran, milnacipran HCl, or to any excipient in

the formulation.• The use of MAOIs intended to treat psychiatric disorders with FETZIMA or within 7 days of stopping treatment with FETZIMA

is contraindicated due to an increased risk of serotonin syndrome. The use of FETZIMA within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated.

• Starting FETZIMA in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated due to an increased risk of serotonin syndrome.

• Do not use FETZIMA in patients with uncontrolled narrow-angle glaucoma.

WARNINGS & PRECAUTIONS • All patients being treated with antidepressants should be monitored appropriately and observed closely for clinical

worsening, suicidality, and unusual changes in behavior, especially during the first few months of treatment and when increasing or decreasing the dose. Consider changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse or includes symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania, or suicidality that are severe, abrupt in onset, or were not part of the patient’s presenting symptoms. Families and caregivers of patients being treated with antidepressants should be alerted about the need to monitor patients daily. Prescriptions for FETZMA should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose.

• Serotonin Syndrome: The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs both when taken alone, but especially when co-administered with other serotonergic agents (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Symptoms of serotonin syndrome may include mental status changes (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms. If symptoms of serotonin syndrome occur, discontinue FETZIMA and initiate supportive treatment. If concomitant use of FETZIMA with other serotonergic drugs is clinically warranted, patients should be aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases.

• SNRIs, including FETZIMA, have been associated with increases in blood pressure. Blood pressure should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing hypertension should be controlled before initiating treatment with FETZIMA. For patients who experience a sustained increase in blood pressure, discontinuation or other appropriate medical intervention should be considered.

• SNRIs including FETZIMA have been associated with an increase in heart rate. Heart rate should be measured prior to initiating treatment and periodically throughout FETZIMA treatment. Pre-existing tachyarrhythmias and other cardiac disease should be treated before starting therapy with FETZIMA. For patients who experience a sustained increase in heart rate, discontinuation or other appropriate medical intervention should be considered.

• SSRIs and SNRIs, including FETZIMA, may increase the risk of bleeding events, some serious. Concomitant use of aspirin, warfarin, NSAIDs and other anticoagulants may add to this risk.

• Mydriasis has been reported in association with SNRIs including FETZIMA; therefore, FETZIMA should be used with caution in patients with controlled narrow-angle glaucoma. Patients with raised intraocular pressure should be monitored. DO NOT use FETZIMA in patients with uncontrolled narrow-angle glaucoma.

• SNRIs, including FETZIMA, can affect urethral resistance. Caution is advised when using FETZIMA in patients prone to obstructive urinary disorders.

• Symptoms of mania/hypomania were reported in 0.2% of FETZIMA-treated patients and 0.2% of placebo-treated patients in clinical studies. As with all antidepressants, FETZIMA should be used cautiously in patients with a history or family history of bipolar disorder, mania or hypomania. Prior to initiating treatment with FETZIMA, patients should be adequately screened to determine if they are at risk for bipolar disorder. FETZIMA is not approved for use in treating bipolar depression.

• FETZIMA should be prescribed with caution in patients with a seizure disorder.• Discontinuation symptoms, some serious, have been reported with discontinuation of serotonergic antidepressants such as

FETZIMA. Gradual dose reduction is recommended, instead of abrupt discontinuation, whenever possible. Monitor patients when discontinuing FETZIMA. If intolerable symptoms occur following a dose decrease or upon discontinuation of treatment, consider resuming the previously prescribed dose and decreasing the dose at a more gradual rate.

• Advise patients that if they are treated with diuretics or are otherwise volume depleted, or are elderly, they may be at greater risk of developing hyponatremia while taking FETZIMA. Although no cases of hyponatremia resulting from FETZIMA treatment were reported in the clinical studies, hyponatremia has occurred as a result of treatment with SSRIs and SNRIs. FETZIMA should be discontinued in patients with symptomatic hyponatremia and appropriate medical intervention should be instituted.

ADVERSE REACTIONS • The most commonly observed adverse reactions in MDD patients treated with FETZIMA in placebo-controlled studies (incidence

≥5% and at least twice the rate of placebo) were: nausea, constipation, hyperhidrosis, heart rate increased, erectile dysfunction, tachycardia, vomiting, and palpitations.

Please refer to the full Prescribing Information for FETZIMA.

xxxxxx xx/2013

Click here to view the full MPR PRESCRIBING ALERT

Lift the burden of depression with FETZIMA™ (levomilnacipran extended-release capsules)

Prescribing Alert®

√ MPR PRescRibing AleRt

FETZIMA™levomilnacipran extended-release capsules

[√] fetZIma has 3 effective dosage strengths: 40 mg, 80 mg, or 120 mg taken once daily1

[√] Dose adjustment for fetZIma is not recommended for a range of patient populations1,4

Important Safety InformatIon

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies. These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients over age 24; there was a reduction in risk with antidepressant use in patients aged 65 and older. In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors. Advise families and caregivers of the need for close obser-vation and communication with the prescriber. FETZIMA is not approved for use in pediatric patients.

company: Forest Pharmaceuticals, Inc.Pharmacologic class: Serotonin and norepinephrine reuptake inhibitor (SNRI).Active Ingredient: Levomilnacipran 20 mg, 40 mg, 80 mg, 120 mg; extended-release capsules.Indication: Treatment of major depressive disorder (MDD). Efficacy and safety for the management of fibromyalgia have not been established.Mechanism of Action: The exact mechanism of the antidepressant action unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters.Dosing: Initially 20 mg once daily for 2 days, and then increase to 40 mg once daily; may increase dose in 40 mg increments at intervals of ≥2 days; max 120 mg once daily.Specific Populations: Pregnancy: Cat. C. Nursing mothers: not recommended. Renal impairment: moderate (CrCl 30–59 mL/min): max 80 mg once daily; severe (CrCl 15–29 mL/min): max 40 mg once daily. ESRD: not recommended. Pediatrics: The safety and effectiveness have not been established.contraindications: During or within 14 days of MAOIs. Concomitant linezolid or IV methylene blue. Uncontrolled narrow-angle glaucoma.Warnings & Precautions: Increased risk of suicidal thinking and behavior in children, adolescents, and young adults; monitor closely for clinical worsening and unusual changes. Monitor for serotonin syndrome; discontinue if develops. Mania/hypomania. Bipolar disorder. Pre-existing hypertension. Cardio- or cerebrovascular disease.

Arrhythmias. Monitor blood pressure (BP) and heart rate (HR); reduce dose or discontinue if elevation persists. Risk of bleeding. Controlled narrow-angle glaucoma. Obstructive urinary disorders. Seizure disorder. Volume depleted. Reevaluate periodically. Write Rx for smallest practical amount. Avoid abrupt cessation. (See Important Safety Information below and throughout.) Drug Interactions: See Contraindications. Allow at least 14 days after MAOI discontinuation before starting levomilnacipran; allow at least 7 days after discontinuing levomilnacipran before starting an MAOI. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, St. John’s Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). Increased risk of bleeding with concomitant NSAIDs, aspirin, anticoagulants; monitor. Concomitant strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, ritonavir): adjust dose to max 80 mg once daily. Avoid alcohol. Caution with other CNS-active drugs, or drugs that can increase BP or HR.Adverse Reactions: Most common (incidence ≥5.0% and at least twice the rate of placebo): nausea, constipation (9.0% vs 3.0%), hyperhidrosis (9.0% vs 2.0%), heart rate increased (6.0% vs 1.0%), erectile dysfunction (6.0% vs 1.0%), tachycardia (6.0% vs 2.0%), vomiting (5.0% vs 1.0%), and palpitations (5% vs 1%).How Supplied: Capsules 20 mg—30 count-bottles; 40 mg, 80 mg, 120 mg—30 count- and 90 count-bottles Titration Pack—1 (2 x 20 mg + 26 x 40 mg).

(continued on next page)

Please see additional Important Safety Information throughout, including Boxed Warning, and enclosed full Prescribing Information.

1

fpo

To: [Healthcare practitioner’s email] Sent: Day, Month XX, 2013From: MPR on behalf of Forest Pharmaceuticals, Inc.Subject: Is recurrent major depression a burden for your patient?

If you are having trouble viewing this email, click here to view it in another browser.

FPO

√ MPR PRESCRIBING ALERT

Extended-release treatment option for major depressive disorder

LEARN MORE

IN YOUR MPR APP INBOX

XX XX/XX